On 1 August 2024, GSK announced that the FDA has approved Jemperli® (dostarlimab) in combination with carboplatin and paclitaxel followed by Jemperli® as a single agent for treating primary advanced or recurrent endometrial cancer. This expands the previous indication for Jemperli® for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer. GSK reports that the new indication includes MMRp/MSS tumours, which represent the majority of endometrial cancer cases.
In June 2022, a study sponsored by GSK and presented at the ASCO annual meeting reported on a small trial of 14 patients with dMMR rectal cancer in which 6 months of dostarlimab treatment led to clinical complete responses in 100% of patients.